EGFR and non-small cell lung carcinoma: Notably, The phase III clinical trial for Almonertinib versus Gefitinib as the first-line treatment for advanced or metastatic NSCLC with EGFR mutation is ongoing, the efficacy as well as the side effects are both needed to be focused on.